Balaji Amines Ltd (BALAMINES) is currently trading at 2,332.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Balaji Amines Limited is an Indian specialty chemical manufacturer producing aliphatic amines, amine derivatives and specialty solvents primarily used by pharmaceuticals, agrochemicals and industrial customers; it operates multiple manufacturing units around Solapur and Medak, exports to 50+ countries and also owns the Balaji Sarovar Premiere five‑star hotel in Solapur. The company reported consolidated Q3FY26 revenue of approximately ₹336 crore with EBITDA of ₹61.7 crore and EBITDA margin around 18.3%; standalone operations are zero‑debt, margins remain resilient near 18–19%, but consolidated PAT and ROCE have moderated year‑to‑date owing to depreciation and ongoing capex. Balaji is pursuing targeted, high‑impact projects: a 100,000 TPA Dimethyl Ether (DME) plant, a 15,000 TPA electronic‑grade DMC facility commissioned for battery chemicals, a 5,000 TPA N‑Methyl Morpholine plant and a Rs.750 crore phased subsidiary expansion to manufacture HCN, NaCN, EDTA and EDA‑based derivatives, with many units aimed for FY2026–27 commissioning. Market positioning is strong: Balaji claims to be India’s largest aliphatic amines and methylamines manufacturer, operates forward integration into derivatives and specialty chemicals, holds REACH and WHO‑GMP certifications and maintains long‑term relationships with blue‑chip pharma customers, supporting export access and pricing resilience. Non‑core diversification exists but is small: the Balaji Sarovar Premiere hotel contributes under 3% of revenue yet reports high occupancy (~82%) and strong RevPAR, delivering incremental cash flow while the chemical business remains the primary earnings driver and focus of management.

Over the past 52 weeks, Balaji Amines Ltd has traded between a low of ₹905.15 and a high of ₹2,627.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Balaji Amines Ltd has a market capitalization of approximately 7,644.37. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Balaji Amines Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.27 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7,644.37 Cr, Balaji Amines Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Balaji Amines Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Balaji Amines Ltd is 36.27. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations was ₹455.92 crore in Q1 FY27, up 27.23% year-on-year from ₹358.34 crore.

The quarterly table shows consolidated total revenue of Rs 358.34 crore and net income (PAT) of Rs 38.00 crore for Q1 FY26.

Consolidated total revenue was reported at INR 403 crore (up 12% YoY). PAT was stated at INR 65 crore, while a filing-based snapshot reported PAT at INR 63.21 crore.

The stock surged after the company reported strong year-on-year growth across revenue, operating profit, and net profit for Q4 FY26 (quarter ended March 2026).